Clinical Trial Update: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the impact of PRO coaching on patient-reported outcomes in frontline advanced or metastatic renal cell carcinoma, comparing sunitinib m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma Metastatic
• Renal Cell Carcinoma Recurrent

Drugs mentioned

• Bavencio (avelumab) (avelumab)
• Inlyta (Axitinib) (Axitinib)
• Keytruda (Pembrolizumab) (pembrolizumab)
• Sutent (sunitinib) (sunitinib)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent | Phase 3 | Status: TERMINATED